Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zerun HPV-9 vs Gardasil 9 Immunogenicity and Safety in Healthy Females
NCT05580341Phase 3Unknown
- Sponsor
- Shanghai Zerun Biotechnology Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of Zerun 9-valent HPV vaccine in human papillomavirus infection, Cervical Cancer (CC), genital warts, vulvar intraepithelial neoplasia (VIN), cervical intraepithelial neoplasia (CIN), sponsored by Shanghai Zerun Biotechnology Co., Ltd.. Status: unknown.
02
Drugs
Zerun 9-valent HPV vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)genital wartsvulvar intraepithelial neoplasia (VIN)cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT05580341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580341.